Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// Ziming Du 1 , Malak Abedalthagafi 1 , Ayal A. Aizer 2 , Allison R. McHenry 3 , Heather H. Sun 1 , Mark-Anthony Bray 4 , Omar Viramontes 5 , Revaz Machaidze 1,5 , Priscilla K. Brastianos 6,7 , David A. Reardon 6 , Ian F. Dunn 5 , Gordon J. Freeman 6 , Keith L. Ligon 1,6 , Anne E. Carpenter 4 , Brian M. Alexander 2 , Nathalie Y. Agar 5 , Scott J. Rodig 1 , Elizabeth M. Bradshaw 3 and Sandro Santagata 1,8 1 Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA 2 Department of Radiation Oncology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA 3 Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA 4 Imaging Platform, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA 5 Department of Neurosurgery, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA 6 Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA 7 Department of Neuro-Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA 8 Department of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA Correspondence: Sandro Santagata, email: // Keywords : meningioma, PD-L1, RNAscope, immunotherapy Received : December 15, 2014 Accepted : December 28, 2014 Published : December 31, 2014 Abstract There are no effective medical treatments for WHO grade III (anaplastic) meningioma. Patients with this high-grade malignancy have a median survival of less than two years. Therapeutics that modulate the mechanisms that inhibit local immune responses in the tumor microenvironment are showing significant and durable clinical responses in patients with treatment refractory high-grade tumors. We examined the immune infiltrate of 291 meningiomas including WHO grade I-III meningiomas using immunohistochemistry and we examined the expression of PD-L1 mRNA by RNAscope in situ hybridization and PD-L1 protein by immunohistochemistry. In meningioma, the tumor infiltrating lymphocytes are predominantly T cells. In anaplastic meningioma, there is a sharp decrease in the number of T cells, including the numbers of CD4+ and CD8+ T cells and cells expressing PD-1 and there is also an increase in the number of FOXP3 expressing immunoregulatory (Treg) cells. PD-L1 expression is increased in anaplastic meningioma – both mRNA and protein. Using patient derived meningioma cell, we confirm that PD-L1 is expressed in meningioma cells themselves, and not solely in infiltrating immune cells. This work indicates that high-grade meningioma harbor an immunosuppressive tumor microenviroment and that increased Treg cells and elevated PD-L1 may contribute to the aggressive phenotype of these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Recent clinical trials of agents targeting PD-1 or PD-L1 have demonstrated durable tumor regression and prolonged stabilization of disease in patients with advanced non-small-cell lung carcinoma, melanoma, renal-cell carcinoma and Hodgkin’s lymphoma [31-35].”
Background(2012) · doi:10.1016/j.jmoldx.2011.08.002 · Cited by 2,567 · cited 1×
“Because the level of PD-L1 is the most important factor for predicting response to anti-PD-1 blockade [36] we have characterized PD-L1 expression using orthogonal techniques – immunohistochemistry and in situ hybridization with RNAscope [37].”
MethodTaube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · cited 1×
“Insights into the molecular mechanisms underlying how the immune system responds to tumors has uncovered the important role of immune checkpoint pathways that regulate the function of tumor infiltrating lymphocytes [26-30].”
Background
Cited by
EANO guidelines for the diagnosis and treatment of meningiomas
Goldbrunner, R., Minniti, G., Preusser, M., Jenkinson, M. D., Sallabanda, K., Houdart, E., von Deimling, A., Stavrinou, P., Lefranc, F., Lund-Johansen, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30321-7 · Cited by 854
Metadata
- Authors
- Du, Z., Abedalthagafi, M., Aizer, A. A., McHenry, A. R., Sun, H. H., Bray, M.-A., Viramontes, O., Machaidze, R., Brastianos, P. K., Reardon, D. A., Dunn, I. F., Freeman, G. J., Ligon, K. L., Carpenter, A. E., Alexander, B. M., Agar, N. Y., Rodig, S. J., Bradshaw, E. M., & Santagata, S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-12-31
- Volume
- 6
- Issue
- 7
- Pages
- 4704-4716
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2109501089
- Cited by
- 179
- References
- 6
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.